MX2010007876A - Vectores virales recombinantes y composicion de vacuna para leishmaniasis. - Google Patents

Vectores virales recombinantes y composicion de vacuna para leishmaniasis.

Info

Publication number
MX2010007876A
MX2010007876A MX2010007876A MX2010007876A MX2010007876A MX 2010007876 A MX2010007876 A MX 2010007876A MX 2010007876 A MX2010007876 A MX 2010007876A MX 2010007876 A MX2010007876 A MX 2010007876A MX 2010007876 A MX2010007876 A MX 2010007876A
Authority
MX
Mexico
Prior art keywords
leishmaniasis
viral vectors
recombinant viral
vaccine composition
leishmania
Prior art date
Application number
MX2010007876A
Other languages
English (en)
Inventor
Gazzinelli Ricardo Tostes
Da Fonseca Flávio Guimarães
Miriam Santos Dutra
Oscar Bruna Romero
Original Assignee
Univ Federal De Minas Gerais Ufmg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Federal De Minas Gerais Ufmg filed Critical Univ Federal De Minas Gerais Ufmg
Publication of MX2010007876A publication Critical patent/MX2010007876A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención describe el uso de vectores virales recombinantes que expresan el antígeno A2 de Leishmania y composiciones de vacunas que son útiles como vacunas contra la leishmaniasis. La invención divulga un método de vacunación inducción-refuerzo que utiliza vectores adenovirales y poxvirales para los fines de vacunación de los mamíferos contra la leishmaniasis. Este método permite la distinción serológica entre individuos vacunados o infectados cuando son examinados mediante ensayos convencionales basados en ELISA o técnicas de inmunofluorescencia que utilizan antígenos dirigidos contra las formas promastigotes de Leishmania.
MX2010007876A 2008-01-17 2009-01-16 Vectores virales recombinantes y composicion de vacuna para leishmaniasis. MX2010007876A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0800485A BRPI0800485B8 (pt) 2008-01-17 2008-01-17 vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
PCT/BR2009/000014 WO2009089605A1 (en) 2008-01-17 2009-01-16 Recombinant viral vectors and vaccine composition for leishmaniasis

Publications (1)

Publication Number Publication Date
MX2010007876A true MX2010007876A (es) 2011-03-03

Family

ID=40885010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007876A MX2010007876A (es) 2008-01-17 2009-01-16 Vectores virales recombinantes y composicion de vacuna para leishmaniasis.

Country Status (4)

Country Link
CN (2) CN108014330A (es)
BR (1) BRPI0800485B8 (es)
MX (1) MX2010007876A (es)
WO (1) WO2009089605A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2795149B2 (es) 2020-06-08 2022-07-04 Univ Madrid Complutense Quimera sintetica multiepitopica como vacuna y tratamiento frente a leishmaniosis en mamiferos
CN113337542A (zh) * 2021-06-10 2021-09-03 山西大学 高效表达利什曼原虫pepck的人复制缺陷型重组腺病毒载体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716697B1 (en) * 1993-09-03 2003-04-02 McGILL UNIVERSITY DIFFERENTIALLY EXPRESSED $i(LEISHMANIA) GENES AND PROTEINS
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6638517B2 (en) * 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ES2109189B1 (es) * 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
IL158124A0 (en) * 2001-03-29 2004-03-28 Univ Mcgill Leishmania vaccines
EP1771571A2 (en) * 2004-07-30 2007-04-11 Targeted Genetics Corporation Recombinant aav based vaccine methods

Also Published As

Publication number Publication date
BRPI0800485B1 (pt) 2021-03-02
BRPI0800485A2 (pt) 2009-09-01
CN108014330A (zh) 2018-05-11
CN102036681A (zh) 2011-04-27
WO2009089605A1 (en) 2009-07-23
BRPI0800485B8 (pt) 2021-05-25
BRPI0800485A8 (pt) 2018-04-17

Similar Documents

Publication Publication Date Title
CY1122872T1 (el) Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
BRPI0518146A (pt) kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
BR112014011229A2 (pt) composições e métodos para o tratamento de citomegalovírus
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
MX2021001638A (es) Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
MX2014009845A (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
BR112013004288A2 (pt) formas galênicas de múltiplos epítopos direcionados para indução de uma resposta imunológica a antigênios.
WO2015142671A3 (en) Influenza virus vectors and uses therefor
EA200701128A1 (ru) Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы
WO2011106607A3 (en) Subunit vaccines for herpes viruses and methods of use
NO20071523L (no) Vaksiner
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
UY31285A1 (es) Vacunas
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
CY1118573T1 (el) Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
CO6670515A2 (es) Vectores de parapoxvirus
NZ596223A (en) Combined measles-malaria vaccine
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
MX2010007876A (es) Vectores virales recombinantes y composicion de vacuna para leishmaniasis.
MX348137B (es) Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
MX2019007924A (es) Vacunas contra la influenza.
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа